Plate Nº 39 · recorded November 14, 2026
Health & Medicine ResearchReported finding
Low Testosterone Linked to 18% Higher Cancer Death Risk in 26,000-Man Study
A review of 26,000 men links low testosterone to an 18% higher risk of cancer death, but researchers warn therapy hasn't been shown to cut that risk.
By Elena Vasquez3 min read666 words
In brief
- Review of 26,000+ men in Australia, the US and Europe, published in The Lancet Healthy Longevity
- Lowest testosterone levels tied to 18% higher relative risk of cancer death; risk rose below 8.6 nmol/L
- Lowest luteinizing hormone levels linked to 45% higher prostate cancer risk; low SHBG to 28% higher
- Testosterone showed no association with prostate cancer itself
- A 2023 trial of 5,000+ men found replacement therapy did not change prostate cancer risk
Men with the lowest testosterone levels face an 18 percent higher relative risk of dying from cancer, according to a systematic review of long-term data from more than 26,000 men in Australia, the United States, and Europe.
The study, published in The Lancet Healthy Longevity, found the risk of developing cancer and dying from it climbed when testosterone sat in the bottom one-fifth of the normal range. And testosterone wasn't acting alone. Three related hormones showed even stronger signals.
What did the four hormones show?
The researchers tracked four hormones and compared men in the lowest one-fifth of levels against those in the highest. The results stack up quickly:
- Testosterone: 18 percent higher relative risk of death from any cancer. Risk started rising when baseline levels fell below 8.6 nmol/L.
- Dihydrotestosterone (DHT): 21 percent higher relative risk of cancer death. DHT is a potent hormone the body makes from testosterone.
- Sex hormone-binding globulin (SHBG): 28 percent higher relative risk of prostate cancer at the lowest levels. SHBG carries testosterone through the bloodstream and controls how much "free" hormone is available.
- Luteinizing hormone: 45 percent higher prostate cancer risk at the lowest levels. The pituitary gland in the brain produces it, and it stimulates testosterone production.
One surprise stood out. Testosterone levels showed no link to prostate cancer at all.
Doesn't testosterone drive prostate cancer?
Doctors routinely lower testosterone to treat prostate cancer, so a connection seemed plausible. This review found none.
"Since reducing testosterone levels is a treatment for prostate cancer there's always been a question of whether the amount of testosterone your own body makes relates to your risk of prostate cancer, but based on our findings there's no evidence they are related," says senior author Bu Yeap, an endocrinologist at The University of Western Australia.
That matters because "low T" has become a catch-all explanation for nearly everything that ails aging men. Online influencers and a booming testosterone replacement industry have pushed that narrative well past what the science supports.
Should men take testosterone to cut cancer risk?
No — and the study's own author says so directly.
"While we've shown low levels are associated with increased risk, we haven't got any evidence yet that actually giving men testosterone will reduce that risk," Yeap says.
A 2023 randomized trial backs that caution. It followed more than 5,000 men with low testosterone for several years and found replacement therapy did not significantly change prostate cancer risk.
Previous research on testosterone and cancer mortality has been mixed, with some studies finding no association at all. This new review has two advantages. It drew only on studies that measured hormones with mass spectrometry, a more accurate lab technique than older methods. It also looked at the family of related hormones together, not testosterone in isolation.
Testosterone, produced by the testes and adrenal glands, shapes sexual function, muscle mass, bone health, and metabolism. Levels normally decline with age. But unusually low levels may signal that something else is wrong.
Yeap puts it plainly: low testosterone could serve as a biomarker of poor health — "so it's possible that looking at testosterone levels could help us identify men who might do poorly if they get cancer down the track."
What should men with low testosterone do?
Get checked. A low reading may not point to testicular disease, but it can flag other health problems worth catching early.
"What we would say to men is if they are found for whatever reason to be low in testosterone, it's important to go to the doctor for a full checkup," Yeap concludes. "It may not show any sign of testicular disease, but it might show other health issues or risk factors they need to address."
The bottom line: low hormone levels look like a warning light on the dashboard, not a cause of cancer — and no evidence yet says replacing the hormone turns that light off.
via sciencealert.com (Source)
More from Elena Vasquez
Show full bio
Correspondent covering money, funding and market shifts around general science news at SciBeat.
422 articles
Nearby plates
- Lifestyle Explains 84% of China's Male-Female Cancer Gap, Just 26% in UK
- American Cancer Society Now Urges Routine PSA Screening for Men 50 to 69
- Higher Tyrosine Levels Linked to Shorter Lifespan in Men, Study Finds
- Out-of-range thyroid levels linked to higher cardiovascular death risk
- X and Y Chromosomes Shape Disease Risk Far Beyond Sex Determination